Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL),(‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal
cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has completed a constructive pre-Investigational New Drug Application (‘pre-IND’) meeting with the U.S. Food and Drug Administration (‘FDA’) for its proprietary drug product
IHL-675A for treatment of rheumatoid arthritis (‘RA’).